COPENHAGEN, July 9 /PRNewswire/ -- Danish specialty pharmaceutical company Egalet has appointed Mr Bertrand Damour as its Chief Financial Officer and Executive Vice President. Mr Damour has extensive experience in the international financial markets and biotechnology industry and will reinforce Egalet’s position in the global pharmaceutical and biotechnology sector.
Egalet a/s is focused on the development of innovative pharmaceutical products utilizing the company’s proprietary, erosion-based, controlled-release technology, Egalet(R), and a novel formulation system, Parvulet(R), aimed at the pediatric market. Its most advanced products are entering late stage clinical trials.
Jan Quistgaard, President and CEO said: I’m delighted that Bertrand has decided to bring his extensive financial and industry experience to Egalet. We have a strong technology platform and an exciting pipeline of late-stage products addressing the cardiovascular disease and pain markets. The pharmaceutical industry is by its nature global and, together with our strong group of investors, Bertrand will further strengthen our international credentials.”
To date, Egalet has raised USD 80 million from leading international and Scandinavian venture capital sources.
Bertrand Damour, the new CFO said: “I am very enthusiastic about my new role with Egalet. The company has an exciting future and I see my new position as an opportunity to build in the experience I have gained in previous international assignments. I have been genuinely impressed by the management’s professionalism and I am proud to be a part of the team.”
Bertrand Damour has a long and successful track record in international banking, including most recently as co-Head of Investment Banking Risk Management at J.P. Morgan in London. Prior to joining J.P. Morgan, Mr Damour held senior-level positions with Deutsche Bank, Bankers Trust and Rabobank International where he was involved in a full range of corporate transactions, including M&As, LBOs and IPOs.
Following his distinguished career in international banking, Mr Damour joined GeneProt a US proteomics company in 2001 where he successively worked as CFO and CEO.
Mr. Damour graduated from the J.L. Kellogg Graduate School of Management at Northwestern University with an MBA degree in Finance and Statistics. He also holds a Master of Engineering degree in Nuclear Physics from the Institut des Sciences de la Matiere et du Rayonnement (ISMRA) and a Masters degree from the Institut d’Administration des Entreprises (IAE).
About Egalet a/s
Egalet a/s is a specialty pharmaceutical company focused on the development of innovative orally administered products utilizing the company’s proprietary, erosion-based, controlled-release technology, Egalet(R) and a novel system, Parvulet(R), aimed at the pediatric market. Egalet’s lead products are entering late-stage clinical studies targeting the cardiovascular and pain markets. They offer significant potential benefits to patients, including improved dosing regimen, increased drug kinetics and biovailability. The Company is based in Copenhagen, Denmark. For more information, visit www.egalet.com
Press contacts Egalet Bertrand Damour, CFO Tel. +45-44478080 Danish enquiries Prospect - Gerhard Dall Tel: +45-3373-0082 International enquiries Citigate Dewe Rogerson Chris Gardner/Valerie Auffray Tel :+44-(0)76389571
Egalet a/s
CONTACT: Press contacts: Egalet, Bertrand Damour, CFO, Tel. +45-44478080;Danish enquiries, Prospect - Gerhard Dall, Tel: +45-3373-0082;International enquiries, Citigate Dewe Rogerson, Chris Gardner/ValerieAuffray, Tel :+44-(0)76389571
